DocGo Inc. DCGO
Medical/Nursing Services · IPO 2020 · data as of November 13, 2026
DocGo Inc. (DCGO) is a healthcare company listed in the US with a market value of about $21M. In the twelve months to September 30, 2026 it had revenue of $297M and net income of -$181M, a net margin of -61.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).
Key numbers: 5-year revenue growth of 28% a year, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 193% above the current price.
About DocGo
DocGo is listed in the US and classified in medical/nursing services, IPO year 2020. Revenue went from $94M in 2020 to $322M in 2025, growth of about 27.9% a year. It was profitable in 4 of the last 6 years in our data. Its share count fell by 4% over three years (buybacks). It spends 4% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $297M | $322M | $617M | $624M | $441M | $319M | $94M |
| Net income | -$181M | -$182M | $20M | $7M | $35M | $24M | -$15M |
| Free cash flow | -$30M | $30M | $67M | -$72M | $26M | -$7M | -$15M |
| EPS (diluted) | $-1.83 | $-1.84 | $0.18 | $0.06 | $0.34 | $0.25 | $-0.25 |
| Net margin | -61.0% | -56.6% | 3.2% | 1.1% | 7.8% | 7.4% | -15.7% |
| ROIC | — | -89.9% | 6.8% | 3.0% | 6.1% | 6.6% | -18.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $1.38, 562% above the current price; targets range from $1.00 to $2.50; the consensus rating is “Buy”; expected EPS is $-0.93 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is DocGo stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 193% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does DocGo pay a dividend?
Not currently.
Is DocGo a good stock to buy?
We do not give buy or sell advice. DocGo scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.